Antibe Therapeutics Inc. (ATE.TO) TSX
Currency In CAD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CAD
Address
15 Prince Arthur Avenue
Toronto, ON M5R 1B2
Canada
Phone
416 922 3460
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
11
First IPO Date
June 18, 2013
| Name | Title | Pay | Year Born |
| Daniel Marcel Legault | President, Chief Executive Officer & Secretary | 744,667 | 1958 |
| Alain Wilson | Chief Financial Officer | 208,581 | N/A |
| Ana Stegic | Executive Director of Clinical Operations | 257,667 | N/A |
| Scott Curtis | Chief Operating Officer | 296,352 | N/A |
| David James Vaughan | Chief Development Officer | 406,583 | 1950 |
| Joseph Stauffer | Chief Medical Officer | 1.11M | 1966 |
| Christina Cameron | Vice President of Investor Relations | 0 | N/A |
| Philip Stern | Vice President of Communications | 0 | N/A |
Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.